Qiagen, LLC

Qiagen, LLC, a foreign-owned subsidiary of Qiagen N.V. headquartered in Germantown, Maryland, is a prime contractor supplying molecular diagnostics equipment, consumables, reagents, and bioinformatics software to federal agencies on a full-and-open basis across the civilian health, defense, and research sectors. The company competes without small business set-asides and maintains no SBA certifications, positioning itself as a specialized supplier of proprietary diagnostic platforms and laboratory instrumentation where competitive sources are limited.

Qiagen's federal capability portfolio centers on DNA and RNA extraction kits, tuberculosis testing reagents (QuantiFERON TB Gold Plus assays), next-generation sequencing equipment and supplies, digital PCR systems, sample preparation instruments (QIAcube and QIAsymphony lines), genomic analysis software (CLC Genomics Workbench and Ingenuity Pathway Analysis), and associated maintenance and support services. Representative work includes a $945,938 delivery order from the National Cancer Institute for evidence-based bioinformatic interpretation of NGS data for precision cancer diagnostics (exercising option period 2); a $917,253 definitive contract with the Animal and Plant Health Inspection Service for CLC Genomics implementation and premium suite software (through August 2029); a $628,634 sole-source preventative maintenance and support services contract with the FBI for QIAGEN instruments supporting NGS validation at the FBI Laboratory Division (through June 2028); and a $403,894 delivery order from FBI Headquarters for QIAGEN reagents and consumables under a $2.5 million IDIQ extending through April 2030.

Customer concentration is heavily weighted toward health and defense agencies. CDC Pittsburgh leads by potential value at $59.2 million across 256 awards, followed by the Defense Health Agency at $42.9 million (71 awards), NIH Office of Logistics and Acquisition Operations at $29.8 million (114 awards), FBI Headquarters at $21.2 million (75 awards), and Army Medical Command at $14.4 million (126 awards). These five account for 56% of the vendor's combined potential value. By award count, the distribution is broader: NIH Office of the Director leads at 676 awards, followed by CDC OAS (279), CDC Pittsburgh (256), NIEHS (254), and Navy Bureau of Medicine and Surgery (242), together representing 26% of all awards but with lower per-award values, indicating small, routine consumables and maintenance task orders.

Qiagen's major parent vehicles are legacy NIH blanket purchase agreements: HHSN263200100054095B (806 task orders, $4.7 million combined value) and HHSN263201500079B (214 task orders, $2.8 million), supplemented by newer single-award BPAs and IDIQs directly with customer agencies. Recently established vehicles include a Defense Health Agency $6.5 million Blanket Purchase Agreement for pharmaceutical products and consumables (awarded March 2025), a Defense Health Agency $489,895 Indefinite Delivery Contract for QuantiFERON TB Gold-Plus assays (through September 2030), Veterans Integrated Service Network 22's $5.12 million Blanket Purchase Agreement for tuberculosis testing reagents (through December 2026), and Veterans Integrated Service Network 15's $553,516 Blanket Purchase Agreement for QuantiFERON reagents at Kansas City VA (through October 2030). The company also holds a $2.5 million FBI IDIQ (through April 2030) and was recently awarded a $924,761 single-award BPA with Veterans Integrated Service Network 19 for reverse transcription PCR GI and respiratory testing services (through September 2027).

Activity has remained relatively flat: 110 awards in 2022, 116 in 2023, 122 in 2024, 96 in 2025 (partial year), and 55 in 2026 (through October 15). Fifty-two awards with ultimate completion dates in the next 24 months carry combined potential value of $5.9 million, presenting recompete exposure for those vehicles. The source notes 6,674 total awards across Qiagen's federal footprint since 1997, with $297.9 million combined potential value and $140.1 million dollars obligated (47% realization rate).

Qiagen's subcontract activity is minimal. Two sub-awards are documented: one to Battelle Memorial Institute (dated March 2025) for service agreements under the National Biodefense Analysis and Countermeasures Center (NBACC) FFRDC contract for ForenSeq UAS Standard Agreement maintenance, and a second to Excet LLC (February 2025) for nucleic acid purification automation support under a DEVCOM CBC biodefense RDT&E BPA call. Two grant sub-awards appear in the source: one to Indiana Department of Health (July 2025) for epidemiology and laboratory capacity under Emerging Infectious Diseases surveillance, and one to Delaware's Executive Office of the Governor (June 2025) for laboratory equipment maintenance. The sub-award footprint is negligible and does not signal a major teaming or subcontracting strategy.

Qiagen's awards cluster heavily in NAICS 334516 (Analytical Laboratory Instrument Manufacturing, 1,676 awards) and 325413 (In-Vitro Diagnostic Substance Manufacturing, 322 awards), with secondary concentration in equipment repair (269 awards) and medical equipment wholesaling (197 awards). By PSC, Laboratory Equipment and Supplies (2,943 awards) dominate, followed by Medical and Surgical Instruments (830) and In Vitro Diagnostic Substances (600). The company's federal customer base spans 136 distinct agencies, reflecting deep penetration across civilian health and research institutions, defense medical commands, law enforcement, and environmental/agricultural research centers. Qiagen competes on the basis of proprietary product validation, sole-source justifications citing exclusive control over patented reagent formulations, and established integration within federal laboratory infrastructure—not price competition or set-aside advantage.